8 results about "Serum mirna" patented technology

The invention relates to an S12micro model for cancer auxiliary diagnosis and prognosis evaluation and application of the S12micro model. According to the method, miRNA expression profiles of more than 20000 cases of samples of 8 common data sets are analyzed, 113 combinations of 12 machine learning algorithms are adopted for modeling and verification, 12 key miRNAs are screened out, and an S12micro model is constructed. The average AUC of the model in a large-scale verification queue is up to 0.987 and is obviously superior to that of the existing 42 serum miRNA marker combinations, and the excellent performance of the serum miRNA marker combination is further verified through clinical samples. The S12micro model is based on a serum sample, does not need invasive operation, has the detection cost lower than that of imaging examination, has the advantages of high sensitivity, high specificity and noninvasiveness, is suitable for early screening and auxiliary diagnosis of various cancers, is higher in universality, can effectively fill the blank of accurate diagnosis and prognosis evaluation of the cancers, and has a wide application prospect. And the method has important practical significance, and has extremely high social value and market application prospect.

The invention belongs to the technical field of miRNA detection, and particularly relates to a biosensor for detecting miRNA, the biosensor comprises a transcription-coupled positive feedback CRISPR / Cas13a system and an electrochemical luminescence hydrogel, the electrochemical luminescence hydrogel is aminocarbazole-sodium alginate-polyethylene glycol hydrogel with the surface modified with gold nanoparticles, and the gold nanoparticles are added to the aminocarbazole-sodium alginate-polyethylene glycol hydrogel. The construction method of the biosensor comprises the following steps: polishing the surface of a glassy carbon electrode on chamois by using aluminum oxide powder, coating the treated surface of the glassy carbon electrode with aminocarbazole-sodium alginate-polyethylene glycol hydrogel with the surface modified with gold nanoparticles, then drying to form a modified film, mixing tris (2-carboxyethyl) phosphine with S1, incubating, and drying to obtain the biosensor with the gold nanoparticle modified amino carbazole-sodium alginate-polyethylene glycol modified amino carbazole-sodium alginate-polyethylene glycol modified amino carbazole-sodium alginate-polyethylene glycol modified amino carbazole-sodium alginate-polyethylene glycol modified amino carbazole-sodium alginate-polyethylene glycol modified amino carbazole. Dropwise adding to the surface of the glassy carbon electrode modified by the hydrogel; the preparation method comprises the following steps: firstly preparing a glassy carbon electrode, then using mercaptohexanol to seal, then capturing pre-prepared DA-S2, reacting and constructing to form an S1-DA-S2 structure, then dropwise adding a transcriptional coupled positive feedback CRISPR / Cas13a system reaction mixed solution to the surface of the glassy carbon electrode, and incubating, so that simple and rapid serum miRNA recognition and nucleic acid signal amplification can be realized. The invention provides a brand new design concept and technical approach for constructing a novel efficient and stable miRNA detection method, and is expected to meet the clinical requirements on high-sensitivity miRNAs detection.

The application discloses a kind of biological sensors for detecting serum miRNA-21 of cervical cancer patient, it is related to the technical field of biosensor.The biological sensor of the application utilizes the large specific surface area of UiO-66-NH2, and Ru (bpy) 3 2+ Molecule (energy donor) and Ag nanoparticle (energy acceptor) are assembled in the same UiO-66-NH2, so that it exhibits high-efficiency intramolecular RET-ECL effect, enhances the ECL sensing response; Based on the stand point mediated strand displacement reaction and catalytic hairpin self-assembly signal amplification strategy, the diversity of substrate selection and the sensitivity of detection are improved; The catalysis of biological enzyme is used to improve the accuracy and timeliness of the biosensor. The biosensor of the application can be applied to the sensitive determination of miRNA-21 in the serum of cervical cancer patients, and has important application value.

The invention discloses a biosensor for detecting serum miRNA-21 of a cervical cancer patient, and relates to the technical field of biosensors. According to the biosensor disclosed by the invention, the Ru (bpy) 3 < 2 + > molecules (energy donors) and the Ag nanoparticles (energy receptors) are assembled in the same UiO-66-NH2 by utilizing the relatively large specific surface area of the UiO-66-NH2, so that the biosensor shows an efficient intramolecular RET-ECL effect, and the ECL sensing response is enhanced; based on a foothold mediated strand displacement reaction and a catalytic hairpin self-assembly signal amplification strategy, the diversity of substrate selection and the sensitivity of detection are improved; the accuracy and timeliness of the biosensor are improved by utilizing catalysis of the biological enzyme. The biosensor provided by the invention can be applied to sensitive determination of miRNA-21 in serum of cervical cancer patients, and has important application value.

This invention relates to the field of biotechnology, specifically the application of miR-541 in the preparation of a non-invasive diagnostic and prognostic assessment kit for liver fibrosis / cirrhosis. This invention utilizes serum miRNA extraction, reverse transcription, and RT-PCR to determine the expression level of miR-541 in the serum of cirrhotic patients. Combined with follow-up information, it confirms a correlation between miR-541 expression and the prognosis of cirrhotic patients. miR-541 can be used to prepare a non-invasive molecular marker for assessing the prognosis of cirrhotic patients, and it also has important guiding significance for preventing or delaying the development of decompensated cirrhosis.

The invention relates to a method for preparing magnetic agarose microspheres based on a hydrogel micro-fluidic system and application of the magnetic agarose microspheres in enrichment and detection of serum miRNA. The magnetic microspheres are prepared through a micro-fluidic chip, agarose with low gel degree is mixed with Fe3O4 as a dispersion phase, ultrasonic uniform mixing is performed, a dropping liquid is prepared, the dropping liquid is collected and frozen, and the magnetic agarose microspheres are obtained. And deoiling and cleaning to obtain the magnetic agarose microspheres. A large number of microspheres with uniform sizes can be rapidly and efficiently prepared through the micro-fluidic chip, and compared with commercialized magnetic beads, the experiment cost is greatly saved; compared with a traditional magnetic agarose microsphere preparation method, the microfluidic method is faster, more efficient and free of pollution, and the prepared microspheres are more attractive. Due to the natural porous structure of agarose, various functional molecules can be coupled, various small biological molecules can be enriched and rapidly separated through magnetic adsorption, and wide application prospects are achieved in the aspects of biological detection, clinical medicine and the like.

The application discloses application of hsa-miR-144-5p as a postmenopausal osteoporosis diagnosis marker. The application adopts high-throughput gene chip technology to detect serum miRNA expression profiles of PMOP patients, and compares with postmenopausal non-osteoporosis population, screens differential expression miRNAs between the two, further verifies the differential level of the selected miRNA between the PMOP patients and n-PMOP through real-time fluorescent quantitative PCR technology, confirms the clinical application value of the screened marker, and finally provides a simple and easy, high-precision biomarker for clinical PMOP diagnosis.

This invention discloses an internal reference gene for the standardization of serum miRNAs in liver cancer and its application. The provided internal reference gene for the standardization of serum miRNAs in liver cancer is selected from any one of three microRNAs, miR-8066, miR-12115, and miR-423-5p, or any combination thereof. It also provides a liver cancer detection kit, including detection reagents or biochips for the specific detection of liver cancer-related target miRNAs and the internal reference gene. Furthermore, it provides a method for the standardized quantification of serum miRNAs in liver cancer, as well as a method for screening standardized internal reference genes for serum miRNAs in liver cancer. This invention provides a reliable standardized tool for the molecular diagnosis and prognostic assessment of liver cancer.